Vernakalant
Standard
Vernakalant : Ein neues Antiarrhythmikum zur Akutbehandlung von Vorhofflimmern. / Hirt, M N; Eschenhagen, Thomas.
in: DEUT MED WOCHENSCHR, Jahrgang 135, Nr. 19, 01.05.2010, S. 971-6.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Vernakalant
T2 - Ein neues Antiarrhythmikum zur Akutbehandlung von Vorhofflimmern
AU - Hirt, M N
AU - Eschenhagen, Thomas
N1 - Georg Thieme Verlag KG Stuttgart * New York.
PY - 2010/5/1
Y1 - 2010/5/1
N2 - Vernakalant is a promising novel antiarrhythmic intravenous drug for the rapid conversion of atrial fibrillation to sinus rhythm. It blocks several ion currents important in cardiac action potential including IKr. Its difference to traditional antiarrhythmic drugs is a preferential effect on the atria, achieved by an inhibition of repolarizing potassium ion currents I(Kur), which is atrial-specific, and I(to), predominantly affecting atrial repolarization, as there is little atrial plateau potential. Furthermore vernakalant blocks frequency- and voltage-dependent sodium ion currents (I(Na)). Thus rapid action potentials in atrial fibrillation are particularly targeted by vernakalant: this leads to a conversion rate to sinus rhythm in about 50 % of recent-onset attacks (less than 7 days) of atrial fibrillation. Age, gender, organ function and concomitant medication seem to have no clinically significant influence on the pharmacokinetics of vernakalant. The number of patients included in the studies is still too small to provide a definitive answer on its cardiac toxicity. However, a demonstrated tendency towards proarrhythmia and little experience with this new drug demands precaution even after it has been officially approved.
AB - Vernakalant is a promising novel antiarrhythmic intravenous drug for the rapid conversion of atrial fibrillation to sinus rhythm. It blocks several ion currents important in cardiac action potential including IKr. Its difference to traditional antiarrhythmic drugs is a preferential effect on the atria, achieved by an inhibition of repolarizing potassium ion currents I(Kur), which is atrial-specific, and I(to), predominantly affecting atrial repolarization, as there is little atrial plateau potential. Furthermore vernakalant blocks frequency- and voltage-dependent sodium ion currents (I(Na)). Thus rapid action potentials in atrial fibrillation are particularly targeted by vernakalant: this leads to a conversion rate to sinus rhythm in about 50 % of recent-onset attacks (less than 7 days) of atrial fibrillation. Age, gender, organ function and concomitant medication seem to have no clinically significant influence on the pharmacokinetics of vernakalant. The number of patients included in the studies is still too small to provide a definitive answer on its cardiac toxicity. However, a demonstrated tendency towards proarrhythmia and little experience with this new drug demands precaution even after it has been officially approved.
KW - Amiodarone
KW - Anisoles
KW - Anti-Arrhythmia Agents
KW - Atrial Fibrillation
KW - Heart Rate
KW - Heart Ventricles
KW - Humans
KW - Membrane Potentials
KW - Pyrrolidines
U2 - 10.1055/s-0030-1253686
DO - 10.1055/s-0030-1253686
M3 - SCORING: Zeitschriftenaufsatz
C2 - 20446233
VL - 135
SP - 971
EP - 976
JO - DEUT MED WOCHENSCHR
JF - DEUT MED WOCHENSCHR
SN - 0012-0472
IS - 19
ER -